The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Open accessAbstract
BACKGROUND: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. METHODS: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart. RESULTS: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern. CONCLUSIONS: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of CATT participants (>92%) had stable or improved VA relative to baseline.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Comparison of AMD Treatments Trials (CATT) showed that bevacizumab was equivalent to ranibizumab in improving visual acuity (VA) of patients with neovascular AMD when treatment was administered either monthly or pro re nata (PRN).1”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“However, despite this remarkable clinical effect, there was a wide range in treatment response.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“At one year, participants treated monthly with bevacizumab or ranibizumab gained 8.0 and 8.5 letters, respectively, and those treated as needed gained 5.9 and 6.8 letters, respectively.”
From Pharmacogenetics for Genes Associated with Age-related Macular Degeneration in the Comparison of AMD Treatments Trials (CATT) (2013) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,781
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M., CASTELLARIN, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,134
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,009
Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
Jacob, J. A., Brié, H., LEYS, A. M., Levecq, L., Mergaerts, F., Denhaerynck, K., Vancayzeele, S., Craeyveld, E. V., Abraham, I. L., & MacDonald, K. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.01.14 · Cited by 37
Lazzeri, S., Ripandelli, G., Sartini, M. S., Parravano, M., Varano, M., Nardi, M., Desidero, T. D., Orlandi, P., & Bocci, G. (2015) · Angiogenesis · doi:10.1007/s10456-015-9483-4 · Cited by 37
Schraermeyer, U., & Julien, S. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2055-z · Cited by 37
Faria-Correia, F., Barros-Pereira, R., Queirós-Mendanha, L., Fonseca, S. L., Mendonça, L. S., Falcão, M. S., Brandão, E., Falcão‐Reis, F., & Carneiro, Â. M. (2013) · Ophthalmologica · doi:10.1159/000346854 · Cited by 37
Nuzzi, R., & Tridico, F. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.835833 · Cited by 37
The ABCs of RVO: A review of retinal venous occlusion
MacDonald, D. (2013) · Clinical and Experimental Optometry · doi:10.1111/cxo.12120 · Cited by 37
Human IgG1 antibodies suppress angiogenesis in a target-independent manner
Bogdanovich, S., Kim, Y., Mizutani, T., Yasuma, R., Tudisco, L., Cicatiello, V., Bastos-Carvalho, A., Kerur, N., Hirano, Y., Baffi, J., et al. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2015.1 · Cited by 37
Asian Age-Related Macular Degeneration
Lim, L. S., Cheung, C. M. G., & Wong, T. Y. (2013) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0b013e31827ff5bc · Cited by 37
Hong, N., Shen, Y., Yu, C., Wang, S., & Tong, J. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13049 · Cited by 38
Counterfeit Avastin in India: Punish the Criminals, Not the Patients
Stewart, M. W., Narayanan, R., Gupta, V., Rosenfeld, P. J., Martin, D. F., & Chakravarthy, U. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.05.023 · Cited by 37
Reeves, B. C., Scott, L. J., Taylor, J., Hogg, R. E., Rogers, C. A., Wordsworth, S., Townsend, D., Muldrew, A., Pető, T., Violato, M., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20800 · Cited by 37
Parvin, P., Zola, M., Dirani, A., Ambresin, A., & Mantel, I. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3762-2 · Cited by 36
Wan, C.-R., Kapik, B. M., Wykoff, C. C., Henry, C. R., Barakat, M., Shah, M., Andino, R. V., & Ciulla, T. A. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.11.27 · Cited by 37
Insight into 144 patients with ocular vascular events during VEGF antagonist injections
Mansour, A. M. (2012) · Clinical ophthalmology · doi:10.2147/opth.s29075 · Cited by 37
Chaudhary, K. M., Romero, J. M., Ezon, I. C., Fastenberg, D. M., & DERAMO, V. A. (2013) · Retina · doi:10.1097/iae.0b013e3182807659 · Cited by 37
Treatment Choice for Diabetic Macular Edema
Martin, D. F., & Maguire, M. G. (2015) · New England Journal of Medicine · doi:10.1056/nejme1500351 · Cited by 37
Chen, G., Li, W., Tzekov, R., Jiang, F., Mao, S., & Tong, Y. (2015) · Retina · doi:10.1097/iae.0000000000000301 · Cited by 36
Hagstrom, S. A., Ying, G.-S., Maguire, M. G., Martin, D. F., Gibson, J., Lotery, A., & Chakravarthy, U. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.04.024 · Cited by 37
Hashimoto, Y., Okada, A., Matsui, H., Yasunaga, H., Aihara, M., & Obata, R. (2022) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00969-2 · Cited by 41
Clinical Applications of Cost Analysis of Diabetic Macular Edema Treatments
Smiddy, W. E. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.015 · Cited by 36
Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation
Parodi, M. B., Iacono, P., Menchini, F., Sheth, S., Polini, G., Pittino, R., & Bandello, F. M. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02265.x · Cited by 36
Fauser, S., & Lambrou, G. N. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.11.002 · Cited by 36
Nieto, A., Hou, H., Moon, S. W., Sailor, M. J., Freeman, W. R., & Cheng, L. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15997 · Cited by 36
Mimoun, G., Caillaux, V., Querques, G., Rothschild, P.-R., Puche, N., & Souied, E. H. (2013) · Retina · doi:10.1097/iae.0b013e3182753adb · Cited by 36
for the OZDRY Study Group, Ramu, J., Yang, Y. C., Menon, G., Bailey, C., Narendran, N., Bunce, C., Quartilho, A., Prevost, A. T., Hykin, P. G., et al. (2015) · Eye · doi:10.1038/eye.2015.214 · Cited by 36
Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases
Yamaguchi, M., Nakao, S., Arima, M., Wada, I., Kaizu, Y., Hao, F., Yoshida, S., & Sonoda, K. (2017) · Journal of Ophthalmology · doi:10.1155/2017/8543592 · Cited by 36
Atrophy in Neovascular Age-Related Macular Degeneration
Domalpally, A., Danis, R. P., Trane, R. M., Blodi, B. A., Clemons, T. E., & Chew, E. Y. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.04.009 · Cited by 36
Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration
Brown, G. C., Brown, M. M., Rapuano, S. B., & Boyer, D. S. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.05.029 · Cited by 36
Ho, A. C., Kleinman, D. M., Lum, F., Heier, J. S., Lindstrom, R. L., Orr, S., Chang, G. C., Smith, E. L., & Pollack, J. S. (2020) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20201104-05 · Cited by 36
de Viteri, M. S., Recalde, S., Fernández‐Robredo, P., Gálvez, M. I. L., Arias, L., Figueroa, M. S., García‐Arumí, J., García‐Layana, A., & The In‐Eye Study Group (2021) · Acta Ophthalmologica · doi:10.1111/aos.14786 · Cited by 36
Self-citationPEDF is an endogenous inhibitor of VEGF-R2 angiogenesis signaling in endothelial cells
Zhang, M., Tombran‐Tink, J., Yang, S., Zhang, X., Li, X., & Barnstable, C. J. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108828 · Cited by 36
Off-Label Prescribing in Older Patients
Jackson, S. H., Jansen, P. A. F., & Mangoni, A. A. (2012) · Drugs & Aging · doi:10.2165/11633520-000000000-00000 · Cited by 36
Galvin, O., Srivastava, A., Carroll, O., Kulkarni, R. S., Dykes, S., Vickers, S. P., Dickinson, K., Reynolds, A., Kilty, C., Redmond, G., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.04.004 · Cited by 37
Peng, C., Chuang, J.-H., Wang, M., Jhan, Y., Chien, K., Chung, Y.-C., Hung, K.-H., Chang, C., Lee, C.-K., Tseng, W.-L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11502 · Cited by 38
Waldstein, S. M., Ritter, M., Simader, C., Sponer, U., Kundi, M., & Schmidt-Erfurth, U. M. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.04.028 · Cited by 35
Zhang, H., Liu, Z.-L., Sun, P., & Gu, F. (2011) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0050 · Cited by 35
Aspirin Use and Risk of Age-Related Macular Degeneration: A Meta-Analysis
Zhu, W. J., Wu, Y., Xu, D., Li, Y., Ba, J., Zhang, X., Wang, F., & Yu, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058821 · Cited by 60
Hautamäki, A., Kivioja, J. L., Vavuli, S., Kakko, S., Savolainen, E., Savolainen, M. J., Liinamaa, J., Seitsonen, S., Onkamo, P., Järvelä, I. E., et al. (2013) · Retina · doi:10.1097/iae.0b013e318285cf92 · Cited by 35
Endophthalmitis Outbreak Associated with Repackaged Bevacizumab
Edison, L. S., Dishman, H., Tobin‐D’Angelo, M., Allen, C. R., Guh, A. Y., & Drenzek, C. L. (2014) · Emerging infectious diseases · doi:10.3201/eid2101.141040 · Cited by 35
Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia
Kanellopoulou, T., & Alexopoulou, A. A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.813478 · Cited by 35
Rajagopal, R., Shah, G. K., Blinder, K. J., Altaweel, M. M., Eliott, D., Wee, R., Cooper, B. A., Walia, H. S., Smith, B. T., & Joseph, D. P. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150909-09 · Cited by 35
Sleeping Beauty Transposon-Mediated Transfection of Retinal and Iris Pigment Epithelial Cells
Johnen, S., Izsvák, Z., Stöcker, M., Harmening, N., Salz, A. K., Walter, P., & Thumann, G. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9951 · Cited by 39
Strittmatter, K., Pomeroy, H., & Marneros, A. G. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.02.018 · Cited by 35
Dong, M., Di, G., Zhang, X., Zhou, Q., & Shi, W. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20926 · Cited by 35
Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
Hanhart, J., Comaneshter, D. S., Freier‐Dror, Y., & Vinker, S. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0586-0 · Cited by 35
Rajavi, Z., Safi, S., Nikkhah, H., Karimi, S., Ahmadieh, H., Azarmina, M., Abrishami, M., Ahoor, M. H., Alizadeh, Y., Behboudi, H., et al. (2018) · Journal of Ophthalmic and Vision Research · doi:10.4103/jovr.jovr_50_18 · Cited by 36
Horita, S., Watanabe, M., Katagiri, M., Nakamura, H., Haniuda, H., Nakazato, T., & Kagawa, Y. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.545 · Cited by 36
An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
Hariprasad, S. M., Gale, R. P., Weng, C. Y., Ebbers, H. C., Rezk, M. F., & Tadayoni, R. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00488-w · Cited by 35
Ilginis, T., Clarke, J. C., & Patel, P. J. (2014) · British Medical Bulletin · doi:10.1093/bmb/ldu022 · Cited by 35
Establishing Equivalence or Non-Inferiority in Clinical Trials
Wellek, S., & Blettner, M. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0674 · Cited by 36
Cordero‐Coma, M., Méndez, R. S., Garzo-García, I., & Yilmaz, T. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.972363 · Cited by 35
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Armendariz, B. G., & Chakravarthy, U. (2024) · Eye · doi:10.1038/s41433-024-03308-6 · Cited by 34
Rap1 GTPase Activation and Barrier Enhancement in RPE Inhibits Choroidal Neovascularization In Vivo
Wittchen, E. S., Nishimura, E., McCloskey, M., Wang, H., Quilliam, L. A., Chrzanowska‐Wodnicka, M., & Hartnett, M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073070 · Cited by 34
Gillies, M. C., Walton, R., Simpson, J. M., Arnold, J., Guymer, R. H., McAllister, I. L., Hunyor, A. P., Essex, R. W., Morlet, N., & Barthelmes, D. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-11993 · Cited by 34
Cho, H. J., Baek, J. S., Lee, D. W., Kim, C. G., & Kim, J. W. (2012) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2012.26.3.157 · Cited by 34
Stewart, M. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4051079 · Cited by 34
Kodjikian, L., Decullier, É., Souied, E. H., Girmens, J., Durand, E., Chapuis, F. R., & Huot, L. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2764-6 · Cited by 34
Baxter, J. M., Fotheringham, A. J., & Foss, A. J. E. (2016) · Eye · doi:10.1038/eye.2016.18 · Cited by 34
Kataja, M., Hujanen, P., Huhtala, H., Kaarniranta, K., Tuulonen, A., & Uusitalo‐Järvinen, H. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-311055 · Cited by 34
Sivertsen, M. S., Jørstad, Ø. K., Grevys, A., Foss, S., Moe, M. C., & Andersen, J. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-20525-8 · Cited by 34
Maugeri, A., Barchitta, M., Mazzone, M. G., Giuliano, F., & Agodi, A. (2018) · BioMed Research International · doi:10.1155/2018/7532507 · Cited by 34
Cui, Q. N., Gray, I. N., Yu, Y., & VanderBeek, B. L. (2019) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-019-04362-7 · Cited by 34
VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration
Waters, S. B., Zhou, C., Nguyen, T., Zelkha, R., Lee, H., Kazlauskas, A., Rosenblatt, M. I., Malik, A. B., & Yamada, K. H. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.2.5 · Cited by 35
Investigational drugs in clinical trials for macular degeneration
Tolentino, M. J., & Tolentino, A. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113375 · Cited by 34
Rahman, H., Yeh, S., & Bergstrom, C. S. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0178 · Cited by 34
Introini, U., Casalino, G., Cardani, A., Scotti, F., Finardi, A., Candiani, M., & Bandello, F. M. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0067 · Cited by 34
Westborg, I., Granstam, E., Rosso, A., Albrecht, S., Karlsson, N., & Lövestam‐Adrian, M. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13539 · Cited by 34
Almuhtaseb, H., Johnston, R. L., Talks, J. S., & Lotery, A. J. (2017) · Eye · doi:10.1038/eye.2017.108 · Cited by 33
Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion
Rush, R. B., Simunovic, M. P., Aragon, A. V., & Ysasaga, J. E. (2014) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20140404-01 · Cited by 33
Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review
Yilmaz, T., & Cordero‐Coma, M. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2016-6 · Cited by 33
Age-related macular degeneration: beyond anti-angiogenesis.
Kent, D. L. (2014) · Europe PMC (PubMed Central) · Cited by 32
Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration
Patel, R. D., Momi, R., & Hariprasad, S. M. (2011) · Seminars in Ophthalmology · doi:10.3109/08820538.2011.570845 · Cited by 32
Melville, H., Carpiniello, M. F., Hollis, K., Staffaroni, A., & Golestaneh, N. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-53 · Cited by 35
Compliance von Patienten mit altersabhängiger Makuladegeneration unter Anti-VEGF-Therapie
Heimes, B., Gunnemann, F., Ziegler, M., Gutfleisch, M., Spital, G., Pauleikhoff, D., & Lommatzsch, A. P. (2016) · Der Ophthalmologe · doi:10.1007/s00347-016-0275-z · Cited by 33
Hussain, R. M., Ciulla, T. A., & Hariprasad, S. M. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20170928-01 · Cited by 33
Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion
Vader, M. J. C., Schauwvlieghe, A.-S. M. E., Verbraak, F. D., Dijkman, G., Hooymans, J. M. M., Los, L. I., Zwinderman, A. H., Pető, T., Hoyng, C. B., van Leeuwen, R., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2019.12.019 · Cited by 33
Müller, P. L., Gliem, M., McGuiness, M. B., Birtel, J., Holz, F. G., & Issa, P. C. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.08.042 · Cited by 32
Longer-acting treatments for neovascular age-related macular degeneration—present and future
Iglicki, M., González, D. P., Loewenstein, A., & Zur, D. (2021) · Eye · doi:10.1038/s41433-020-01309-9 · Cited by 33
Wang, Y., Zhang, Q., Yang, G., Wei, Y., Li, M., Du, E., Li, H., Song, Z., & Tao, Y. (2021) · Drug Delivery · doi:10.1080/10717544.2020.1870584 · Cited by 34
Nguyen, V., Barthelmes, D., & Gillies, M. C. (2021) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13949 · Cited by 32
Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery
Cheng, J.-W., Cheng, S., Wei, R.-L., & Lu, G. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009782.pub2 · Cited by 32
Lemos, V., Cabugueira, A., Noronha, M., Pinto, L. A., Reina, M., Branco, J., & Gomes, T. (2015) · Ophthalmologica · doi:10.1159/000369478 · Cited by 33
Li, T., Hou, X., Deng, H. X., Zhao, J., Huang, N., Zeng, J., Chen, H., & Gu, Y. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00412d · Cited by 33
Lushchyk, T., Amarakoon, S., Ciriano, J. P. M., van den Born, L. I., Baarsma, G. S., & Missotten, T. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12119 · Cited by 33
Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab
Park, S. C., Su, D., & Tello, C. A. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.721772 · Cited by 33
Mineralocorticoid pathway in retinal health and diseases
Béhar‐Cohen, F., & Zhao, M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15770 · Cited by 32
Guthrie, S., Bienkowska-Gibbs, T., Manville, C. M., Pollitt, A., Kirtley, A., & Wooding, S. (2015) · Health Technology Assessment · doi:10.3310/hta19670 · Cited by 34
Liarakos, V. S., Papaconstantinou, D., Vergados, I. A., Douvali, M., & THEODOSSIADIS, P. G. (2013) · European Journal of Ophthalmology · doi:10.5301/ejo.5000391 · Cited by 32
Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents
Singh, R. S., & Kim, J. E. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0031-2 · Cited by 32
Automated Segmentation of Pathological Cavities in Optical Coherence Tomography Scans
Pilch, M., Stieger, K., Wenner, Y., Preising, M. N., Friedburg, C., zu Bexten, E. M., & Lorenz, B. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-11396 · Cited by 32
Vascular Endothelial Growth Factor-A Increases the Aqueous Humor Outflow Facility
Fujimoto, T., Inoue, T., Maki, K., Inoue-Mochita, M., & Tanihara, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161332 · Cited by 32
Hanhart, J., Comaneshter, D. S., Freier‐Dror, Y., & Vinker, S. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-3917-9 · Cited by 32
Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration
Lorés‐Motta, L., de Jong, E. K., & den Hollander, A. I. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0332-1 · Cited by 32
Teo, K. Y. C., Gillies, M. C., & Fraser‐Bell, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092611 · Cited by 32
Jaggi, D., Nagamany, T., Ebneter, A., Munk, M. R., Wolf, S., & Zinkernagel, M. S. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316514 · Cited by 34
Menon, G., Chandran, M., Sivaprasad, S., Chavan, R., Narendran, N., & Yang, Y. C. (2013) · Eye · doi:10.1038/eye.2013.93 · Cited by 32
Meredith, E. L., Mainolfi, N., Poor, S. H., Qiu, Y., Miranda, K., Powers, J. J., Liu, D., Ma, F., Solovay, C., Rao, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01227 · Cited by 32
SOLID-APPEARING RETINAL CYSTS IN DIABETIC MACULAR EDEMA
Liang, M. C., Vora, R. A., Duker, J. S., & Reichel, E. (2013) · Retinal Cases & Brief Reports · doi:10.1097/icb.0b013e31828eef49 · Cited by 32
Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario
Jain, P., Sheth, J. U., Anantharaman, G., & Gopalakrishnan, M. (2017) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_992_16 · Cited by 32
Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice
Veritti, D., Sarao, V., Gorni, G., & Lanzetta, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020265 · Cited by 31
Metadata
- Authors
- The CATT Research Group
- Corresponding author
- The CATT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-19
- Volume
- 364
- Issue
- 20
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3157322
- OpenAlex
- W1481978003
- Cited by
- 2,669
- References
- 21
- Citations by year
- 2026: 78 · 2025: 91 · 2024: 116 · 2023: 111 · 2022: 127 · 2021: 164 · 2020: 195 · 2019: 151 · 2018: 168 · 2017: 177 · 2016: 199 · 2015: 238 · 2014: 264 · 2013: 248 · 2012: 265
- FWCI
- 254.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (U10EY017825, U10EY017826, U10EY017823, U10EY017828)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, ranibizumab, bevacizumab, intravitreal injection, anti-VEGF therapy, visual acuity, central retinal thickness, treatment schedule, non-inferiority, serious adverse events, off-label drug use, anti-angiogenic therapy, comparative efficacy and safety, hospitalization
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cardiovascular Diseases, Drug Administration Schedule, Female, Humans, Macular Degeneration, Male, Middle Aged, Retina, Therapeutic Equivalency, Visual Acuity, Proportional Hazards Models, Single-Blind Method, Off-Label Use, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
